Subtitle
Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study.
Subtitle
Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study.
Proto therapy Time
November 2020
Executive summary
22 patients with T1 to T2 N0M0 NSCLC received image-guided hypofractionated PBT to a total dose 48 GyRBE in 4 fractions for peripheral lesions and 60 GyRBE in 10 fractions for central lesions. The overall survival rates at 3 and 5 years were 81% and 49%. One patient (5%) developed a late grade 3 bronchial stricture requiring hospitalization and stent.
Key content topics
Top cancer treatments
Other popular content
Proton Therapy Publication
December 2021
Technical insights on the treatment of GI cancers.
Proton Therapy Publication
October 2021
Impact of lymphopenia on the clinical outcomes of esophageal cancer patients
Proton Therapy Publication
October 2021
Acute Hematological Outcomes in Pediatric Brain Tumors
Proton Therapy Publication
October 2021
Comparison of hypothyroidism and adrenal insufficiency in children with medulloblastoma
Proton Therapy Publication
October 2021
Acute Hematological Outcomes after Proton and Photon Beam Craniospinal Irradiation in Pediatric Brain Tumors
Proton Therapy Publication
September 2021
Scoping review of patient selection methods for proton therapy
Proton Therapy Publication
September 2021
Reduced diffusion in white matter after radiotherapy with photons and protons
Proton Therapy Publication
September 2021
Particle Radiotherapy for Skull Base Chondrosarcoma
Proton Therapy Publication
September 2021
Dosimetry, efficacy, safety, and cost-effectiveness of PT for NSCLC
Proton Therapy Publication
September 2021
Current status and application of proton therapy for esophageal cancer
Proton Therapy Publication
September 2021
Assessing concordance between patient-reported and investigator-reported CTCAE after PBT for prostate cancer.
Proton Therapy Publication
September 2021
Bicentric Treatment Outcomes following PT for Non-Myxopapillary High-Grade Spinal Cord Ependymoma in Children
Proton Therapy Publication
September 2021
Identifying individualized risk profiles for radiotherapy-induced lymphopenia
Proton Therapy Publication
September 2021
FLASH proton radiotherapy spares normal epithelial and mesenchymal tissues while preserving sarcoma response
Proton Therapy Publication
August 2021
Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma